Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
arcticnovartis
Mon, 11/20/2023 – 07:19
Read more about Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS a…
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis
Thu, 11/09/2023 – 17:04
Read more about Novartis data show potential of …
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
arcticnovartis
Thu, 11/09/2023 – 17:04
Read more about Novartis data show potential of …
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
arcticnovartis
Tue, 10/31/2023 – 22:04
Read more about FDA approves Novartis Cosentyx® as the first new biologic tre…
FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
arcticnovartis
Tue, 10/31/2023 – 22:04
Read more about FDA approves Novartis Cosentyx® as the first new biologic tre…
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 10/30/2023 – 07:34
Read more about Novarti…
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
arcticnovartis
Thu, 10/26/2023 – 22:19
Read more about Novartis confirms unconstrained supply for Pluvicto® and continues to …
Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more abo…
Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more abo…
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more a…